Invesco Biotechnology & Genome ETF Rating $67.68 -0.16 (-0.24%) As of 01/17/2025 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOwnershipRatings Invesco Biotechnology & Genome ETF Aggregate Rating and Price Target (2025)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.PBE Aggregate RatingModerate Buy 2.71Holdings in PBE have an aggregate rating of Moderate Buy based on 444 analyst ratings issued in the past year covering 30 companies (99.9% of the portfolio).PBE Aggregate Price Target$67.68High Prediction$67.68Average Prediction$67.68Low Prediction$67.68Holdings in PBE have an aggregate price target of $67.68 and a range of $67.68 to $67.68 covering 30 companies (99.9% of the portfolio).PBE Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy7 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Invesco Biotechnology & Genome ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 30 PBE Holdings Export to ExcelWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings5.40%NTRANatera$158.36-6.0%2.1961 of 5 stars3.00$160.63 1.4%16Analyst ForecastNews CoverageHigh Trading Volume5.00%UTHRUnited Therapeutics$358.93-2.0%4.9225 of 5 stars2.73$378.36 5.4%15Analyst UpgradeInsider TradeShort Interest ↓News CoveragePositive News5.00%INCYIncyte$71.93-0.7%4.7352 of 5 stars2.35$76.29 6.1%20Analyst ForecastShort Interest ↓News Coverage4.96%GILDGilead Sciences$91.84+0.2%4.3921 of 5 stars2.70$97.96 6.7%27Insider TradeShort Interest ↑Analyst RevisionNews Coverage4.92%REGNRegeneron Pharmaceuticals$681.58-1.7%4.6562 of 5 stars2.65$1,015.38 49.0%23Analyst ForecastNews Coverage4.89%ILMNIllumina$136.67-0.5%4.6418 of 5 stars2.70$165.63 21.2%20Short Interest ↓News Coverage4.78%BIIBBiogen$140.55-0.5%4.7047 of 5 stars2.43$230.00 63.6%28Short Interest ↑4.52%AMGNAmgen$272.11+1.0%4.8818 of 5 stars2.44$314.91 15.7%27News CoveragePositive NewsGap Up3.09%HALOHalozyme Therapeutics$54.80-1.0%4.583 of 5 stars2.60$60.89 11.1%10Short Interest ↑Analyst Revision3.04%BCRXBioCryst Pharmaceuticals$7.45+5.5%4.4267 of 5 stars2.83$15.17 103.6%6Short Interest ↓High Trading Volume3.02%SRPTSarepta Therapeutics$118.00+0.8%4.9454 of 5 stars2.91$178.71 51.5%22Analyst ForecastAnalyst RevisionNews Coverage2.99%NBIXNeurocrine Biosciences$143.26+0.9%4.8742 of 5 stars2.83$164.81 15.0%23Insider TradeNews Coverage2.97%COLLCollegium Pharmaceutical$33.35-0.3%4.2842 of 5 stars2.80$43.80 31.3%5Insider Trade2.95%CPRXCatalyst Pharmaceuticals$22.78+0.5%4.7206 of 5 stars3.00$32.86 44.2%7Short Interest ↑High Trading Volume2.92%ACADACADIA Pharmaceuticals$17.57+0.3%4.0025 of 5 stars2.59$25.25 43.7%17Short Interest ↑News Coverage2.92%VCYTVeracyte$40.58-1.3%3.9993 of 5 stars2.67$41.13 1.3%9Analyst UpgradePositive NewsHigh Trading Volume2.88%BMRNBioMarin Pharmaceutical$61.53+0.5%4.9993 of 5 stars2.74$94.20 53.1%23Options VolumeNews CoverageHigh Trading Volume2.87%QGENQiagen$46.00+0.2%4.184 of 5 stars2.56$51.50 12.0%9Short Interest ↓News Coverage2.82%EXASExact Sciences$51.74+2.6%4.76 of 5 stars2.94$72.94 41.0%18News CoverageGap UpHigh Trading Volume2.77%TECHBio-Techne$75.83-0.4%4.0665 of 5 stars2.63$82.00 8.1%82.73%CDNACareDx$21.44-2.8%3.7123 of 5 stars2.57$28.33 32.2%7Analyst ForecastShort Interest ↑Analyst RevisionNews Coverage2.72%RPRXRoyalty Pharma$30.75-0.6%4.7732 of 5 stars3.00$41.67 35.5%7Dividend IncreaseOptions Volume2.65%BPMCBlueprint Medicines$110.05+5.9%1.6812 of 5 stars2.65$122.72 11.5%20Analyst ForecastInsider TradeShort Interest ↑Analyst RevisionNews Coverage2.60%EXELExelixis$36.20-1.0%4.5373 of 5 stars2.53$35.50 -1.9%19Analyst ForecastShort Interest ↑Analyst RevisionNews Coverage2.58%MYGNMyriad Genetics$12.39-1.0%4.0883 of 5 stars2.00$23.92 93.0%13Analyst ForecastShort Interest ↑News Coverage2.52%MNKDMannKind$6.013.9405 of 5 stars3.13$9.07 50.9%8Short Interest ↓Positive News2.47%XNCRXencor$19.24-3.9%4.2167 of 5 stars3.11$36.56 90.0%9Positive News2.32%AXSMAxsome Therapeutics$91.93-1.9%4.6819 of 5 stars3.00$130.69 42.2%13Analyst Revision2.28%TGTXTG Therapeutics$29.55+1.4%4.4928 of 5 stars2.83$40.67 37.6%6Analyst ForecastAnalyst RevisionNews Coverage2.27%PTGXProtagonist Therapeutics$36.82+0.8%3.045 of 5 stars3.00$53.78 46.1%9News Coverage This page (NYSEARCA:PBE) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsoredliberals FOOLED by Elon’s shocking surpriseElon Musk and Donald Trump fooled everyone. They said it was to “save free speech”... Or “fix what the l...StocksToTrade | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invesco Biotechnology & Genome ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Invesco Biotechnology & Genome ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBE Stock Alerts